A
Arcutis
Focuses on medical dermatology, leveraging innovations in inflammation and immunology
About Arcutis
Arcutis Biotherapeutics is a biopharmaceutical company specializing in the development of innovative therapies for dermatological diseases. The company focuses on filling the innovation gap in medical dermatology by leveraging recent advancements in inflammation and immunology. Arcutis serves patients suffering from skin conditions such as psoriasis, eczema, and seborrheic dermatitis. Operating in the biopharmaceutical market, the company employs a business model centered around research and development, clinical trials, and commercialization of its proprietary drug formulations. Revenue is generated through the sale of these specialized therapies once they receive regulatory approval. The leadership team, which includes top dermatologists and a leading topical drug formulator, brings unparalleled expertise to the company's mission of becoming a leader in dermatological innovation.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Listing
- IPO 2020
News
Knowledge graph
Open roles
Arcutis in the Thousand Oaks ecosystem
The Arcutis office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Frazier Healthcare Partners
OrbiMed
Series B and later3 investors entered at this stage
HBM Healthcare Investments
Vivo Capital
SLR Capital Partners
Source: Dealroom Talent Intelligence.
Patents
32 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
See Arcutis on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

